Showing 1471-1480 of 1616 results for "".
- NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreementhttps://modernod.com/news/novabay-pharmaceuticals-expands-avenovas-geographic-reach-to-australia-with-new-exclusive-distribution-agreement/2478586/NovaBay Pharmaceuticals announced the signing of an agreement with Paragon Care Group Australia Pty for the exclusive distribution of Avenova in Australia. Paragon Care Group will begin distributing Avenova directly to consumers under its Designs For Vision brand beginning in early 2021. “
- AstraZeneca, J&J Say Their COVID-19 Vaccine Trials Back on Track in UShttps://modernod.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/AstraZeneca announced Friday that it has been cleared to restart its phase 3 COVID-19 vaccine trial in the US. The company, which is co-developing AZD1222 with the University of Oxford, had paused global testing of the vaccine candidate early last month after a UK participant fell ill with what i
- Sources Say US Study of AstraZeneca’s COVID-19 Vaccine May Restart This Weekhttps://modernod.com/news/sources-say-us-study-of-astrazenecas-covid-19-vaccine-may-restart-this-week/2478439/According to a report Tuesday citing four sources, the US trial of AstraZeneca’s COVID-19 vaccine AZD1222 is expected to resume as early as this week after the FDA completed its review of a serious adverse event that had prompted a hold on global testing of the candidate last month. The pha
- Oxular Receives Rare Paediatric Disease and Orphan-Drug Designations for Retinoblastoma Treatmenthttps://modernod.com/news/oxular-receives-rare-paediatric-disease-and-orphan-drug-designations-for-retinoblastoma-treatment/2478404/Oxular Limited announces it has received both rare paediatric disease and orphan drug designations from the FDA for OXU-003, the company’s proprietary drug in development for the treatment of retinoblastoma. Retinoblastoma is a rare form of eye cancer that usually develops in early childho
- GSK, Vir Biotechnology Move Anti-SARS-CoV-2 Monoclonal Antibody Into Phase 3https://modernod.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/GlaxoSmithKline and partner Vir Biotechnology announced that the COMET-ICE study evaluating VIR-7831 as an early treatment for COVID-19 patients deemed to be at high risk of hospitalization will proceed into phase 3 testing, with preliminary results coming possibly before the end of this year. Th
- Glaucoma Study Findings Emphasize Need for Regular Eye Checkshttps://modernod.com/news/glaucoma-study-findings-emphasize-need-for-regular-eye-checks/2478048/People with early-stage glaucoma see the contrast of visible objects in a very similar way to people without the condition, a new study has shown. Research by the University of Bradford (UK) demonstrated that the brain compensates for the changes in the eye caused by glaucoma, when looking
- Novavax Gains $1.6 Billion in Funding for COVID-19 Vaccine Candidatehttps://modernod.com/news/novavax-gains-1-6-billion-in-funding-for-covid-19-vaccine-candidate/2477984/Novavax announced that it has been awarded $1.6 billion by the US government to progress development of NVX CoV2373 and potentially deliver 100 million doses of the COVID-19 vaccine as early as late 2020. NVX‑CoV2373 consists of a stable, prefusion protein made using Novavax’s nanop
- Gilead Looking to Test Easier-To-Use, Inhaled Version of Remdesivirhttps://modernod.com/news/gilead-to-begin-human-trials-for-the-inhaled-version-of-coronavirus-drug-remdesivir/2477919/Gilead Sciences said Monday that it hopes to begin clinical trials this summer evaluating an inhaled formulation of remdesivir, administered via a nebuliser, to patients with COVID-19. The experimental antiviral, which the FDA authorized for emergency use in early May, is currently given intraven
- Oxford Biomedica Snags Manufacturing Equipment to Ramp Up Production of COVID-19 Vaccinehttps://modernod.com/news/oxford-biomedica-snags-manufacturing-equipment-to-ramp-up-production-of-covid-19-vaccine/2477880/In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca’s manufacturing partners has struck a deal for n
- Moderna Secures FDA Approval to Advance Coronavirus Vaccine Candidate mRNA-1273 to Phase 2 Testinghttps://modernod.com/news/moderna-secures-fda-approval-to-advance-coronavirus-vaccine-candidate-mrna-1273-to-phase-2-testing/2477729/Moderna said the FDA is allowing it to move ahead with a phase 2 study of its experimental COVID-19 vaccine mRNA-1273. Moderna stated that it will begin the study with 600 participants “shortly” and is finalising the protocol for a phase 3 trial to start early this summer, with CEO St